Key Insights from Attending ASH 2025

Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC Recorded on February 19, 2026 Matthew Kutny, MD Professor of Pediatrics Director, Leukemia, Lymphoma and Histiocytosis Program Director, Pediatric Clinical Trials Office Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN) Pediatric Hematology and Oncology University of Alabama at Birmingham Birmingham, AL Julie Guillot Pediatric AML parent, global advocate, and Blood Cancer United Volunteer Kelly Laschinger, MSN, RN, CPNP, CPHON Director, Clinical Trial Support Center Blood Cancer United Washington, DC In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access! Blood Cancer United Resources: Clinical Trial Support Center Information Resource Center Dare to Dream Project Pediatric Acute Leukemia Master Clinical Trial (PedAL) Mentioned on this episode: Project Facilitate This episode is supported by the Tom Reich Educational Endowment Fund.

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Pam Simon, MSN, CPNP, CPON, Stanford Adolescent and Young Adult Cancer Program (SAYAC), Palo Alto, CA and H. Irene Su, MD MSCE, University of California San Diego, San Diego, CA Recorded on January 20, 2026 Pam Simon, MSN, CPNP, CPON Nurse Practitioner & Program Manager Stanford Adolescent and Young Adult Cancer Program (SAYAC) Palo Alto, CA H. Irene Su, MD MSCE Professor Reproductive Endocrinology and Infertility Fellowship Director Division of Reproductive Endocrinology and Infertility Co-Director, Center for Obstetrics and Gynecology Research Innovations Department of Obstetrics, Gynecology and Reproductive Sciences Director, Moores Cancer Center Leadership Academy University of California San Diego San Diego, CA In this episode, we’re joined by Dr. Irene Su, Professor of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego, and Pam Simon, Nurse Practitioner and Program Manager of the Stanford Adolescent and Young Adult (AYA) Cancer Program at Stanford Medicine. They discuss fertility risk across treatment types, approaches to fertility preservation and reproductive survivorship planning, insurance and access considerations, and the cultural and sociodemographic factors that shape care. They also share strategies to support shared decision-making and promote psychosocial well being for AYA patients and survivors. Tune in for practical insights to strengthen your approach to fertility care for AYAs. Mentioned on this episode: OncofertilityRisk.com The Alliance for Fertility Preservation Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT Recorded on January 8, 2026 Chelsey Winegar, LCSW, MBA Manager of Oncology Services Intermountain Health Murray, UT Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve. Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today! Mentioned on this episode: Trauma Stewardship Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Medical Debt Case Management Program for Patients Blood Cancer United Additional Resources for Patients

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!

Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice! This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.

Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, CPNP, CPHON Director, Clinical Trial Support Center Blood Cancer United Washington, DC Sarah K. Tasian, MD Blood Cancer United PedAL Master Clinical Trial Lead Associate Professor of Pediatrics, University of Pennsylvania School of Medicine Chief of Hematologic Malignancies Program, Children’s Hospital of Philadelphia Philadelphia, PA Join us for our first episode as Blood Cancer United! In this episode, Dr. Sarah Tasian, from Children’s Hospital of Philadelphia, and Ann Collins and Kelly Laschinger, from Blood Cancer United, join us for an in-depth discussion on pediatric acute leukemias. The conversation delves into the latest therapies, treatment challenges, and the complex realities of long-term survivorship. We also explore the groundbreaking Blood Cancer United Pediatric Acute Leukemia Master Clinical Trial (PedAL), its bold vision, global collaboration, and unified approach to data collection. Valuable clinical trial resources and strategies to support patients, families, and healthcare professionals are also shared. Tune in today!